Holen Sie sich die Stockscreener-App
2.995
4.01%
-0.125
Schlusskurs vom Vortag:
$3.12
Offen:
$3.18
24-Stunden-Volumen:
776.98K
Relative Volume:
0.56
Marktkapitalisierung:
$190.11M
Einnahmen:
$139.77M
Nettoeinkommen (Verlust:
$-97.62M
KGV:
-1.8956
EPS:
-1.58
Netto-Cashflow:
$-61.71M
1W Leistung:
+34.30%
1M Leistung:
+75.15%
6M Leistung:
+88.36%
1J Leistung:
+36.14%
1-Tages-Spanne:
$2.9741
$3.25
1-Wochen-Bereich:
$2.25
$3.54
52-Wochen-Spanne:
$0.9897
$3.54
Macrogenics Inc Stock (MGNX) Company Profile
Firmenname
Macrogenics Inc
Sektor
Branche
Telefon
301-251-5172
Adresse
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
2.9912 | 198.29M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.01 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.43 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.43 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.58 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.48 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2024-11-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-31 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-05-10 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-04-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-03-04 | Bestätigt | BTIG Research | Buy |
| 2024-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-22 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-11-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-02-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-04 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Hochstufung | Barclays | Underweight → Overweight |
| 2020-12-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2019-12-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Guggenheim | Neutral |
| 2019-02-07 | Hochstufung | Citigroup | Sell → Buy |
| 2019-02-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-02-06 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-12-10 | Herabstufung | Raymond James | Outperform → Underperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-05-31 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-31 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Macrogenics Inc Aktie (MGNX) Neueste Nachrichten
MacroGenics at Barclays Conference: Strategic Therapeutic Focus By Investing.com - Investing.com Canada
MGNX: Multiple clinical milestones and strategic updates expected in 2026, backed by strong partnerships - TradingView
MacroGenics (NASDAQ:MGNX) Price Target Raised to $4.00 at Barclays - Defense World
MacroGenics (MGNX) Loss Of US$74.6 Million Tests Bullish Loss‑Narrowing Narrative - Sahm
MacroGenics at Leerink Global Healthcare Conference: Strategic Pipeline Focus By Investing.com - Investing.com Canada
Stifel reiterates MacroGenics stock rating with $4 price target - Investing.com
MacroGenics Inc earnings missed by $0.03, revenue topped estimates - Investing.com Nigeria
Barclays Forecasts Strong Price Appreciation for MacroGenics (NASDAQ:MGNX) Stock - MarketBeat
MacroGenics (NASDAQ:MGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS - MarketBeat
Barclays Raises Price Target for Macrogenics (MGNX) to $4.00, Maintains 'Overweight' Rating | MGNX Stock News - GuruFocus
MacroGenics, Inc. 2025 Annual Report: Innovative Antibody-Based Cancer Therapeutics, Pipeline, and Risk Factors Overview - Minichart
MGNX Closes Up 45% On Wall Street Optimism For Experimental Cancer Therapies - Stocktwits
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures - Bitget
MacroGenics: Fourth Quarter Earnings Overview - Bitget
MacroGenics Q4 2025 Earnings: Loss Below Estimates, Revenue Beats ForecastNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
MacroGenics: Q4 Earnings Snapshot - marketscreener.com
Cancer biotech MacroGenics lines up 2026 trial data, funds into 2027 - Stock Titan
Chipmakers Recap: Can MacroGenics Inc expand its profit margins2026 Macro Moves & Low Risk Growth Stock Ideas - baoquankhu1.vn
Aug Breakouts: Can MacroGenics Inc disrupt its industryPortfolio Value Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Risk Off: Will MacroGenics Inc. stock deliver consistent dividends2025 Growth vs Value & Detailed Earnings Play Strategies - Naître et grandir
Aug Retail: Will MacroGenics Inc outperform the market in YEARJuly 2025 Macro Moves & Long-Term Growth Plans - baoquankhu1.vn
Trade Recap: Can MacroGenics Inc expand its profit marginsWeekly Volume Report & Long-Term Growth Stock Strategies - baoquankhu1.vn
MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts - MarketBeat
MGNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MacroGenics (MGNX) director Jay Siegel to step down after 2026 meeting - Stock Titan
Whats the profit margin of MacroGenics IncEarnings Risk Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus
MacroGenics to Participate in Upcoming Investor Conferences - The Manila Times
Cancer drug developer MacroGenics lines up March investor talks - Stock Titan
FDA Partially Pauses Cancer Drug Trial After Patient Death - National Today
Why is MacroGenics stock sinking Tuesday? - MSN
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates - MSN
MacroGenics stock falls after FDA places partial clinical hold - Investing.com South Africa
MacroGenics stock falls after FDA places partial clinical hold By Investing.com - Investing.com Australia
MacroGenics (MGNX) Faces FDA Setback with Partial Hold on Lorige - GuruFocus
MacroGenics stock drops after FDA partial hold (MGNX:NASDAQ) - Seeking Alpha
FDA Places Partial Clinical Hold on MacroGenics Trial - TipRanks
FDA Imposes Partial Clinical Hold on MacroGenics' (MGNX) Study - GuruFocus
MacroGenics Pauses Cancer Drug Trial After Safety Issues - National Today
MacroGenics Pauses Enrollment Of Participants In LINNET Trial On FDA's Partial Clinical Hold - RTTNews
MacroGenics says FDA places partial clinical hold on Phase 2 LINNET study - TipRanks
Why Is MacroGenics Stock Sinking Tuesday? - Bitget
FDA halts new enrollment in MacroGenics (NASDAQ: MGNX) LINNET study - Stock Titan
Macrogenics announces pausing of enrollment of new study participants in Linnet trial - marketscreener.com
MacroGenics Faces Partial Clinical Hold from FDA on LINNET Study of Lorigerlimab in Gynecologic Cancers - Quiver Quantitative
FDA halts new enrollment in cancer trial after severe side effects - Stock Titan
Panic Selling: Will MacroGenics Inc outperform the market in YEAR2025 Performance Recap & Weekly Setup with High ROI Potential - baoquankhu1.vn
Armistice Capital (MGNX) discloses 6.32M shares, 9.99% stake via Master Fund - Stock Titan
MacroGenics (NASDAQ: MGNX) SVP awarded RSUs, options and exercises units - Stock Titan
MacroGenics (MGNX) VP Beth Ann Smith reports RSU vesting and new option grants - Stock Titan
Finanzdaten der Macrogenics Inc-Aktie (MGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):